Brief: New Data Confirms Performance Of Decisiondx-Melanoma To Identify Patients With Less Than 5% Risk Of Sentinel Lymph Node Positivity
14/11/2025 12:07
Nov 14 (Reuters) - Castle Biosciences Inc CSTL.O: NEW DATA CONFIRMS PERFORMANCE OF DECISIONDX®-MELANOMA TO IDENTIFY PATIENTS WITH LESS THAN FIVE PERCENT RISK OF SENTINEL LYMPH NODE POSITIVITY Source text: ID:nGNX6PG95m Further company coverage: CSTL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Castle Biosciences
See all newsBrief: Castle Biosciences, - Opens New Laboratory And Office Facility In Scottsdale, Arizona
U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Castle Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Castle Biosciences beats Q2 revenue estimates, hikes forecast
Brief: Castle Biosciences Q2 Revenue USD 103.546 Million Vs. IBES Estimate USD 86.2 Million